Recommendations to lower the risk of tuberculosis in patients treated with tumour necrosis factor alpha antagonists.
Gómez-Reino
Juan
J
Servicio de Reumatología, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, España.
Carmona
Loreto
L
D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D006801:Humans; D000069285:Infliximab; D011174:Portugal / Q000453:epidemiology; D017410:Practice Guidelines as Topic; D012042:Registries; D012307:Risk Factors; D013030:Spain / Q000453:epidemiology; D014376:Tuberculosis / Q000139:chemically induced* / Q000453:epidemiology / Q000517:prevention & control*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab